Exagen Inc.
NASDAQ:XGNMedical - Diagnostics & Research
+$0.16 today
- Market cap
- $99.50M
- Beta
- 2.02
- P/E (TTM)
- -5.2
- EPS (TTM)
- -$0.85
Volume 0.47M
Average 0.39M
XGN Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Exagen Inc.NASDAQ: XGN
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development growth accelerates
Q1 FY2026 research & development of $1.55M rose 21.0% year over year, ahead of the +16.5% change in trailing-twelve-month research & development. Sequentially, it fell 11.6% from the prior quarter. Over 3 fiscal years it compounded at -14.1% a year.
Context
- Research & development amounted to 9.4% of revenue in FY2025, down 0.3 pp from a year earlier.
- Research & development increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +21.0% holds above the trailing-twelve-month pace of +16.5%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 6.25M USD
- Year-over-year change
- +16.4%
- 4-year CAGR
- -3.6%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 6.25M | +16.4% |
| FY2024 | 2024-12-31 | 5.38M | +10.5% |
| FY2023 | 2023-12-31 | 4.87M | -50.7% |
| FY2022 | 2022-12-31 | 9.88M | +36.5% |
| FY2021 | 2021-12-31 | 7.24M | — |
Research & Development vs competitors
How XGN compares with its peers on the latest reported figures
- XGN's LTM Mar 2026 research & development of $6.52M is the 9th highest of the 11 companies compared; the peer median is $11.54M.
- Its year-over-year change of +16.5% is the 3rd highest of 10, against a peer median of -1.9%.
- Research & development amounts to 9.5% of revenue for XGN, versus a peer median of 12.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $101.99M | +14.6% | +8.4% | 46.8% | |
BIOABioAge Labs, Inc. | LTM Mar 2026 | $83.27M | +36.9% | +34.3% | 807.2% |
| LTM Mar 2026 | $56.72M | +60.6% | -12.2% | 677.9% | |
| LTM Jun 2026 | $38.17M | +9.5% | +6.9% | 5.0% | |
| LTM Mar 2026 | $12.72M | -28.5% | -13.9% | 16.0% | |
| FY2025 | $10.35M | -1.9% | +11.1% | 9.6% | |
| LTM Mar 2026 | $9.43M | -4.4% | -3.9% | 30.2% | |
| LTM Mar 2026 | $7.58M | — | +1.8% | 5.6% | |
| LTM Mar 2026 | $6.52M | +16.5% | -14.1% | 9.5% | |
| LTM Mar 2026 | $5.08M | -13.4% | +14.6% | 4.7% | |
| LTM Mar 2026 | $2.25M | -8.0% | -34.3% | 5.4% | |
| Peer median (excluding XGN) | $11.54M | -1.9% | +4.3% | 12.8% | |
Competitors are the stored peer set for XGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 48.3M | 45.56M | 52.55M | 55.64M | 66.58M |
| Cost of Revenue | 20.59M | 24.21M | 23.09M | 22.53M | 27.78M |
| Gross Profit | 27.71M | 21.35M | 29.46M | 33.11M | 38.8M |
| Gross Margin | 57.4% | 46.9% | 56.1% | 59.5% | 58.3% |
| Research & Development | 7.24M | 9.88M | 4.87M | 5.38M | 6.25M |
| Selling, General & Admin | 44.54M | 52.02M | 47.43M | 41.37M | 46.62M |
| Operating Expenses | 51.78M | 67.4M | 52.29M | 46.75M | 52.87M |
| Depreciation & Amortization | 948K | 1.56M | 2.17M | 1.72M | 2.12M |
| EBITDA | (23.1M) | (43.66M) | (19.15M) | (11.15M) | (13.46M) |
| EBITDA Margin | -47.8% | -95.8% | -36.4% | -20.0% | -20.2% |
| Operating Income | (24.07M) | (46.05M) | (22.84M) | (13.64M) | (14.07M) |
| Operating Margin | -49.8% | -101.1% | -43.5% | -24.5% | -21.1% |
| Interest Income | 16K | 830K | 1.52M | 767K | 289K |
| Interest Expense | 2.63M | 2.45M | 2.34M | 2.23M | 4.32M |
| Other Income / Expenses | (2.61M) | (1.62M) | (819K) | (1.47M) | (5.83M) |
| Income Before Tax | (26.68M) | (47.67M) | (23.66M) | (15.1M) | (19.9M) |
| Pre-Tax Margin | -55.2% | -104.6% | -45.0% | -27.1% | -29.9% |
| Income Tax Expense | 175K | (282K) | 33K | 12K | 51K |
| Net Income | (26.85M) | (47.39M) | (23.69M) | (15.12M) | (19.95M) |
| Net Margin | -55.6% | -104.0% | -45.1% | -27.2% | -30.0% |
| EPS (Basic) | (1.68) | (2.77) | (1.34) | (0.83) | (0.93) |
| EPS (Diluted) | (1.68) | (2.77) | (1.34) | (0.83) | (0.93) |
| Weighted Avg Shares | 15.97M | 17.08M | 17.68M | 18.2M | 21.56M |
| Weighted Avg Shares (Diluted) | 15.97M | 17.08M | 17.68M | 18.2M | 21.56M |
Exagen Inc.
NASDAQ:XGN
Intrinsic Alpha fair value
Locked
Current Price
$3.90
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.